Rephonic
Artwork for Flot.bio x Philip Hemme

Flot.bio x Philip Hemme

Flot.bio
Biotechnology
Clinical Trials
Biotech
Biopharma
Ulcerative Colitis
Rare Diseases
Drug Development
Abivax
Immunotherapy
Cell Therapy
Antibody-Drug Conjugates
EU Biotech
Cancer Vaccines
Venture Capital
Gene Therapy
Pharmaceutical Industry
Diversity In Biotech
Novo Holdings
Cardior
Biotech Industry

Watch the #1 Biotech Podcast in Europe to grow. Hosted by Philip Hemme. 25k monthly views. Free. Guests include Antoine Papiernik @Sofinnova, Werner Lanthaler @Evotec, Ingmar Hoerr @CureVac, Bernat Olle @Vedanta, Johannes Fruehauf @BioLabs, Rodger Novak @CRISPR Tx, Agnete Fredriksen @Nykode, Mike Ward, Thomas Clozel @Owkin, Marc de Garidel @Abivax, Sander van Deventer @VectorY & Forbion, Jens Niel... more

PublishesTwice monthlyEpisodes63Founded3 years ago
Number of ListenersCategories
Life SciencesScience

Listen to this Podcast

Artwork for Flot.bio x Philip Hemme

Latest Episodes

Regina Hodits, who I have known for many years, spent 15 years at Wellington Partners before joining Angelini Ventures in 2025. The corporate venture fund now manages close to €500M, and its first exit, Noctrix Health, sold to ResMed for $340M in Jun... more

Christophe has run MedinCell since 2009, when it was eight people in a converted garage. Today it's one of only three French biotechs to ever cross $1B on Euronext.With one Teva-partnered product already a commercial success, the partners are potenti... more

Christian Angermayer became a multimillionaire before turning 25 thanks to the merger of Alnylam with Ribopharma. We talk about his diverse investment appetite and the rise of consumer biotech and human enhancement.We talk about GLP-1s, the progress ... more

After ImCheck’s inception in 2015, Pierre took the helm through clinical development and guided the startup to a $1.2B buyout by Ipsen in 2025.

In a session at the Kadans Oncology Summit, he talks about how the exit materialised and the oncology spa... more

Key Facts

Accepts Guests
Accepts Sponsors
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Biotech Hangout
Biotech HangoutDaphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more
Founders
FoundersDavid Senra

Recent Guests

Regina Hodits
Investor, Angelini Ventures
Angelini Ventures
Episode: Red Hot Rare Diseases and Europe’s record funding with Regina Hodits, Angelini Ventures | E63
Christophe Douat
CEO of MedinCell
MedinCell
Episode: MedinCell CEO on Long-Acting Drugs & France’s $1B Biotech Club | Christophe Douat | E62
Christian Angermayer
Billionaire investor focused on biotech, psychedelics, longevity, and consumer biotech
Apeiron
Episode: Billionaire wild bets on Consumer Biotech, GLP-1s, and psychedelics | Christian Angermayer | E61
Pierre d'Epenoux
Founder/CEO of ImCheck (during the story)
ImCheck
Episode: ImCheck ex-CEO on ASCO Oncology Trends, $1.2B Exit and French Biotech | Pierre d’Epenoux | E60
Jean-François Brepson
CEO, PathoQuest
PathoQuest
Episode: CEO Jean-François Brepson on Scaling a CRO, and Selling to Charles River | E59 [Sponsored]
Hervé Hoppenot
Former CEO of Incyte
Incyte
Episode: Ex-CEO of Incyte Hervé Hoppenot on 10x Growth, Biotech Cycles, and Breaking Bureaucracy | E58
Christoph Lengauer
Co-founder of Curie.Bio
Curie.Bio
Episode: Christoph Lengauer, Curie.Bio | Biotech Founders, Venture Capital | E57
Sander van Deventer
Co-founder of Forbion, prominent biotech investor
Forbion
Episode: Sander Slootweg, Forbion 🇳🇱 | European Biotech Investment, Venture Capital | E56
Pedro (Immunethep)
Co-founder of Immunethep
Immunethep
Episode: Solving Antimicrobial Resistance, Vaccines, Antibiotics | Immunethep 🇵🇹 | E55 [Sponsored]

Host

Philip Hemme
Host of Flot.bio Show

Reviews

4.6 out of 5 stars from 30 ratings
  • One of the best video podcasts for Biotech

    I’m one of the founders so I’m a bit biased. But if it try to listen to it as a user, I find it to be one of the best video podcasts, especially with Europeans speakers and mostly for a European audience. Would love to hear what you think

    Apple Podcasts
    5
    phm12345
    Germany3 years ago

Listeners Say

Key themes from listener reviews, highlighting what works and what could be improved about the show.

European biotech guests are always top-tier; insights are practical for investors and founders.
High-quality, data-driven discussions from seasoned executives; great for understanding biotech funding cycles.
Strong focus on European market dynamics and exits; helpful for sponsorship decisions.

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Talking Points

Recent interactions between the hosts and their guests.

MedinCell CEO on Long-Acting Drugs & France’s $1B Biotech Club | Christophe Douat | E62
Q: What are the plans for patient access in the developing world?
The company is evaluating Uzedy and Olanzapine LAI for use in developing countries, supported by foundations and a focus on lowering cost of goods sold to enable widespread access and data generation to support potential approvals in those regions.
MedinCell CEO on Long-Acting Drugs & France’s $1B Biotech Club | Christophe Douat | E62
Q: How did Teva influence MedinCell's trajectory and access to markets?
Teva served as an agile, large pharma partner that embraced New Therapeutic Entities, helping bring MedinCell's technology to a broader pipeline while maintaining a lean, drug-delivery-focused culture.
MedinCell CEO on Long-Acting Drugs & France’s $1B Biotech Club | Christophe Douat | E62
Q: What makes Uzedy different from earlier long-acting injectables, and what has its market uptake looked like so far?
Uzedy stands out due to its rapid achievement of therapeutic levels after a single injection and a favorable PK/PD profile, translating into strong uptake, high patient adherence, and a market forecast of potential multi-hundred-million dollars in peak sales as payers and clinicians recognize its value.
ImCheck ex-CEO on ASCO Oncology Trends, $1.2B Exit and French Biotech | Pierre d’Epenoux | E60
Q: What was the strategy that allowed ImCheck to pursue an exit over remaining independent?
The strategy combined strong data generation, a clear clinical path with phase transition planning (moving from phase one to seamless phase two/three), and building a capable team with investors willing to support a strategic exit when the right partner and timing aligned. External data supports were used to de-risk the pathway, and multiple funding rounds kept the company buoyant while preparing for the sale.
Solving Antimicrobial Resistance, Vaccines, Antibiotics | Immunethep 🇵🇹 | E55 [Sponsored]
Q: What stages of product development are you currently pursuing and what are the regulatory implications?
The team moved from broad mechanism-based validation to family-specific formulations to simplify regulatory pathways, with emphasis on immunogenicity, safety in mice models, and GMP-scaleability to meet regulatory requirements.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About Flot.bio x Philip Hemme

What is Flot.bio x Philip Hemme about and what kind of topics does it cover?

Across recent episodes, the show centers on European biotech, investing, and company-building at the intersection of science and business. Conversations frequently cover biotech funding trends, exits and acquisition strategies, regulatory landscapes, and the evolving role of CROs, vaccine development, and novel platforms in oncology, immunotherapy, and cell therapy. A notable thread is how European ecosystems are maturing to support world-class startups, with practical lessons for founders, investors, and corporate partners, often anchored by first-hand stories from veteran executives and investors. The format tends to blend strategic insights with personal leadership perspectives, offering actionable takeaways for fundraising, partnerships... more

Where can I find podcast stats for Flot.bio x Philip Hemme?

Rephonic provides a wide range of podcast stats for Flot.bio x Philip Hemme. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to Flot.bio x Philip Hemme and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does Flot.bio x Philip Hemme get?

Rephonic provides a full set of podcast information for four million podcasts, including the number of listeners. View further listenership figures for Flot.bio x Philip Hemme, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for Flot.bio x Philip Hemme?

Rephonic provides comprehensive predictive audience data for Flot.bio x Philip Hemme, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does Flot.bio x Philip Hemme have?

To see how many followers or subscribers Flot.bio x Philip Hemme has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to Flot.bio x Philip Hemme?

These podcasts share a similar audience with Flot.bio x Philip Hemme:

1. BioCentury This Week
2. Biotech Hangout
3. All-In with Chamath, Jason, Sacks & Friedberg
4. The Knowledge Project
5. Founders

How many episodes of Flot.bio x Philip Hemme are there?

Flot.bio x Philip Hemme launched 3 years ago and published 63 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact Flot.bio x Philip Hemme?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for Flot.bio x Philip Hemme?

Rephonic pulls ratings and reviews for Flot.bio x Philip Hemme from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for Flot.bio x Philip Hemme?

Rephonic provides full transcripts for episodes of Flot.bio x Philip Hemme. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on Flot.bio x Philip Hemme?

Recent guests on Flot.bio x Philip Hemme include:

1. Regina Hodits
2. Christophe Douat
3. Christian Angermayer
4. Pierre d'Epenoux
5. Jean-François Brepson
6. Hervé Hoppenot
7. Christoph Lengauer
8. Sander van Deventer

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days